Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.65 |
| ▸ | CDK4 | P11802 | 5/20 | 0.61 |
| ▸ | CCND3 | P30281 | 4/20 | 0.61 |
| ▸ | CCND1 | P24385 | 3/20 | 0.61 |
| ▸ | CCND2 | P30279 | 3/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CCNK | O75909 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371810 | 0.86 | KDM1A (0.62) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29368254 | 0.86 | MAP4K1 (0.60) | MAP4K1EGFRALKAURKACCNA2 | |
| SCHEMBL29576526 | 0.85 | WEE1 (0.56) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29576898 | 0.85 | HTR3A (0.68) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29372589 | 0.84 | ALK (0.67) | EGFRALKCDK4CCND1CDK2 | |
| SCHEMBL29575732 | 0.84 | SYK (0.56) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29575978 | 0.84 | MAP4K1 (0.55) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29576356 | 0.84 | JAK3 (0.56) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29576068 | 0.84 | MAP4K1 (0.72) | MAP4K1EGFRALKCDK4CCND3 | |
| SCHEMBL29576631 | 0.83 | MAP4K1 (0.54) | MAP4K1EGFRALKCDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDK3, CDK1 | MAP4K1 529/4885EGFR 831/4885ALK 2531/4885 |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAP4K1 16/4885EGFR 518/4885ALK 692/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP4K1 16/4885EGFR 518/4885ALK 692/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP4K1 16/4885EGFR 518/4885ALK 692/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP4K1 16/4885EGFR 518/4885ALK 692/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAP4K1 16/4885EGFR 518/4885ALK 692/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | MAP4K1 25/4885EGFR 290/4885ALK 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.